Loading...
Docoh

Bio-Rad Laboratories (BIO)

Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, its products advance the discovery process and improve healthcare. Bio-Rad's customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020.

Company profile

Ticker
BIO, BIO.B
Exchange
Website
CEO
Norman Schwartz
Employees
Incorporated
Location
Fiscal year end
Former names
BIO RAD LABORATORIES INC
SEC CIK
Subsidiaries
Bio-Rad Laboratories Pty Ltd • DiaMed Österreich GmbH • Bio-Rad Laboratories NV • Research Specialties for Laboratories NV • DiaMed Benelux NV • Bio-Rad Laboratórios Brasil Ltda. • DiaMed Latino-América S.A. • Bio-Rad Laboratories (Rishon), Inc. • Bio-Rad Pacific Limited • Bio-Rad Laboratories (Canada) Limited ...
IRS number
941381833

BIO stock data

Analyst ratings and price targets

Last 3 months

Calendar

29 Jul 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 596.91M 596.91M 596.91M 596.91M 596.91M 596.91M
Cash burn (monthly) 68.58M 11.69M 407.63M 217.48M (no burn) (no burn)
Cash used (since last report) 99.25M 16.91M 589.88M 314.71M n/a n/a
Cash remaining 497.66M 579.99M 7.03M 282.19M n/a n/a
Runway (months of cash) 7.3 49.6 0.0 1.3 n/a n/a

Beta Read what these cash burn values mean

My notes
No notes yet
My annotations
No annotations yet
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Aug 22 Ajit Ramalingam Bio-Rad A Common Stock Sell Dispose S No No 537 518 278.17K 98.497
29 Apr 22 Last Andrew J. Bio-Rad A Common Stock Payment of exercise Dispose F No No 512.06 471 241.18K 2,293.122
29 Apr 22 Last Andrew J. Bio-Rad A Common Stock Option exercise Acquire M No No 0 1,000 0 2,764.122
29 Apr 22 Last Andrew J. RSU Bio-Rad A Common Stock Option exercise Dispose M No No 0 1,000 0 2,000
29 Apr 22 Ajit Ramalingam Bio-Rad A Common Stock Payment of exercise Dispose F No No 512.06 96 49.16K 601.688
29 Apr 22 Ajit Ramalingam Bio-Rad A Common Stock Option exercise Acquire M No No 0 277 0 697.688
29 Apr 22 Ajit Ramalingam RSU Bio-Rad A Common Stock Option exercise Dispose M No No 0 277 0 831
76.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 497 522 -4.8%
Opened positions 63 83 -24.1%
Closed positions 88 56 +57.1%
Increased positions 187 183 +2.2%
Reduced positions 184 190 -3.2%
13F shares Current Prev Q Change
Total value 10.61B 14.34B -26.0%
Total shares 18.87M 19.02M -0.7%
Total puts 147.9K 128.5K +15.1%
Total calls 101.2K 54.2K +86.7%
Total put/call ratio 1.5 2.4 -38.4%
Largest owners Shares Value Change
Vanguard 2.32M $1.31B +1.3%
BLK Blackrock 1.76M $991.36M -0.4%
STT State Street 984.53K $554.52M -2.4%
FMR 930.21K $523.92M -51.8%
Alliancebernstein 652.75K $367.65M +11.3%
Brown Advisory 581.92K $328.7M +7.9%
Marshall Wace 467.34K $263.23M +40.2%
Geode Capital Management 439.12K $247.02M +2.9%
Acadian Asset Management 415.53K $234.01M +1.0%
BAC Bank Of America 394.5K $222.19M +6.4%
Largest transactions Shares Bought/sold Change
FMR 930.21K -998.11K -51.8%
Millennium Management 289.91K +261.32K +914.1%
Intermede Investment Partners 0 -226.8K EXIT
Norges Bank 0 -213.29K EXIT
Marshall Wace 467.34K +133.97K +40.2%
Renaissance Technologies 187.8K +131.6K +234.2%
Citadel Advisors 135.76K +127.65K +1572.8%
Nitorum Capital 110.56K +110.56K NEW
Tikvah Management 97.03K +97.03K NEW
Alliancebernstein 652.75K +66.26K +11.3%

Financial report summary

?
Management Discussion
  • Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period monthly average foreign exchange rates for that currency and comparing that to current period sales.
  • Net sales (sales) for the second quarter of 2022 were $691.1 million compared to $715.9 million in the second quarter of 2021, a decrease of 3.5%.  COVID-related sales were approximately $33.2 million in the second quarter of 2022 compared to approximately $69.0 million reported in the second quarter of 2021. Excluding the impact of foreign currency, second quarter 2022 sales increased by approximately 0.5% compared to the same period in 2021. Currency neutral sales increased in both the Americas and EMEA, partially offset by decreased sales in Asia due to COVID lockdowns in China during the second quarter of 2022 that negatively impacted our diagnostics business. Excluding COVID-related sales, revenue increased 5.7% on a currency neutral basis from the second quarter of 2021.
  • The Life Science segment sales for the second quarter of 2022 were $322.4 million, a decrease of 3.5% compared to the same period last year.  On a currency neutral basis, sales increased 0.5% compared to the second quarter in 2021. The currency neutral sales growth was primarily attributed to increased sales of Process Media, Western Blotting, and Droplet Digital PCR products, despite supply chain constraints having an impact on instrument placements. The sales increases were partially offset by lower qPCR product revenue due to the decline in COVID-19 related demand. Currency neutral sales increased in both Asia Pacific and the Americas, while Europe was essentially flat.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: bank, characteristic, COVID, differentiate, flat, fraud, Immunology, improper, lockdown, phishing, procuring, putting, redirect, stop, stronger, unrecoverable, vendor
Removed: Approximate, authority, begin, chosen, curtail, draft, end, enforcing, Expression, Gene, granting, large, premarket, renegotiating, resigning, reviewed, slower, sovereign, submission, transferring, voted

Patents

Utility
System and Method for Isolating and Analyzing Cells
11 Aug 22
A system and method for isolating and analyzing single cells, comprising: a substrate having a broad surface; a set of wells defined at the broad surface of the substrate, and a set of channels, defined by the wall, that fluidly couple each well to at least one adjacent well in the set of wells; and fluid delivery module defining an inlet and comprising a plate, removably coupled to the substrate, the plate defining a recessed region fluidly connected to the inlet and facing the broad surface of the substrate, the fluid delivery module comprising a cell capture mode.
Utility
Compositions and Methods for Molecular Labeling
11 Aug 22
The invention provides barcode libraries and methods of making and using them including obtaining a plurality of nucleic acid constructs in which each construct comprises a unique N-mer and a functional N-mer and segregating the constructs into a fluid compartments such that each compartment contains one or more copies of a unique construct.
Utility
System and Method for Isolating and Analyzing Cells
11 Aug 22
A system and method for isolating cells, comprising: a substrate having a broad surface; an array comprising a set of wells defined at the broad surface of the substrate, each well including: a base surface, an open surface directly opposing the base surface, defined at the broad surface of the substrate, and configured to receive one of a single cell and a single cluster of cells from a direction perpendicular to the broad surface of the substrate, and a set of channels that fluidly couple each well to at least one adjacent well; wherein the set of wells includes an interior subset and an exterior subset fluidly coupled to and surrounding the interior subset by way of the set of channels; and a fluid delivery module surrounding the array and fluidly coupled to each well in the set of wells.
Utility
Methods for Processing Nucleic Acid Samples
28 Jul 22
The present disclosure provides methods and systems for amplifying and analyzing nucleic acid samples.
Utility
Digital analyte analysis
19 Jul 22
The invention generally relates to droplet based digital PCR and methods for analyzing a target nucleic acid using the same.